[go: up one dir, main page]

AR054786A1 - (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1 - Google Patents

(6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1

Info

Publication number
AR054786A1
AR054786A1 ARP060102607A ARP060102607A AR054786A1 AR 054786 A1 AR054786 A1 AR 054786A1 AR P060102607 A ARP060102607 A AR P060102607A AR P060102607 A ARP060102607 A AR P060102607A AR 054786 A1 AR054786 A1 AR 054786A1
Authority
AR
Argentina
Prior art keywords
metanomas
dioxolil
morfolin
benzol
fluor
Prior art date
Application number
ARP060102607A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR054786A1 publication Critical patent/AR054786A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Método de preparacion. Composiciones farmacéuticas que las contienen y usos, para el tratamiento y/o profilaxis de enfermedades asociadas con la modulacion de receptores de CB1, tales como la obesidad. Reivindicacion 1: Compuestos de la formula (1) en la que R1 se elige entre el grupo formado por H, F o Cl; R2 es H o Cl; y las sales farmacéuticamente aceptables de los mismos.
ARP060102607A 2005-06-22 2006-06-20 (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1 AR054786A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05105516 2005-06-22

Publications (1)

Publication Number Publication Date
AR054786A1 true AR054786A1 (es) 2007-07-18

Family

ID=36933609

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102607A AR054786A1 (es) 2005-06-22 2006-06-20 (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1

Country Status (16)

Country Link
US (2) US20060293318A1 (es)
EP (1) EP1896445B1 (es)
JP (1) JP2008543912A (es)
KR (1) KR100970055B1 (es)
CN (1) CN101203502A (es)
AR (1) AR054786A1 (es)
AT (1) ATE487707T1 (es)
AU (1) AU2006260997A1 (es)
BR (1) BRPI0612125A2 (es)
CA (1) CA2612079A1 (es)
DE (1) DE602006018143D1 (es)
ES (1) ES2353818T3 (es)
IL (1) IL188037A0 (es)
MX (1) MX2007015779A (es)
TW (1) TW200740787A (es)
WO (1) WO2006136502A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
BR112012003973A2 (pt) 2009-08-26 2015-09-08 Sanofi Sa hidratos de fluoroglicosídeo heteroaromático cristalinos, produtos farmacêuticos compreendendo estes compostos e seu uso
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN105210038B (zh) 2013-05-15 2018-10-30 英派尔科技开发有限公司 核亲和性位掩码变换
CN108445136A (zh) * 2018-03-20 2018-08-24 常州市盛辉药业有限公司 一种高效液相色谱法分离测定2，4-二氯苯乙酮和2，6-二氯苯乙酮异构体的方法
CN108445137A (zh) * 2018-03-20 2018-08-24 常州市盛辉药业有限公司 一种高效液相色谱法分离测定2，4-二氯苯乙酮和邻甲基苯乙酮的方法
WO2023205180A1 (en) 2022-04-19 2023-10-26 Nurix Therapeutics, Inc. Biomarkers for cbl, and compositions and methods for their use
US20230414598A1 (en) 2022-06-22 2023-12-28 Nurix Therapeutics, Inc. Combination therapies with cbl-b inhibitor compounds and antiemetic agents

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940418A (en) * 1972-04-07 1976-02-24 G. D. Searle & Co. Esters and amides of 4,5-dihydrobenz[g]indazole-3-carboxylic acids and related compounds
DE611366T1 (de) * 1991-11-07 1995-04-06 Dow Chemical Co Chlorierungsverfahren, Alkylierung der Produkte dieses Prozesses und einigedieser Produkte.
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2714057B1 (fr) * 1993-12-17 1996-03-08 Sanofi Elf Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
FR2741621B1 (fr) * 1995-11-23 1998-02-13 Sanofi Sa Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
IL141769A0 (en) * 1998-09-11 2002-03-10 Aventis Pharma Sa Azetidine derivatives, preparation and medicines containing them
US6479479B2 (en) * 2000-03-03 2002-11-12 Aventis Pharma S.A. Azetidine derivatives, their preparation and pharmaceutical compositions containing them
US6355631B1 (en) * 2000-03-03 2002-03-12 Aventis Pharma S.A. Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
US6566356B2 (en) * 2000-03-03 2003-05-20 Aventis Pharma S.A. Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
US6509367B1 (en) * 2001-09-22 2003-01-21 Virginia Commonwealth University Pyrazole cannabinoid agonist and antagonists
BR0313041A (pt) * 2002-07-29 2005-06-21 Hoffmann La Roche Compostos; composições farmacêuticas; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação dos receptores de cb1; e uso de compostos
US20040259887A1 (en) * 2003-06-18 2004-12-23 Pfizer Inc Cannabinoid receptor ligands and uses thereof

Also Published As

Publication number Publication date
KR20080015478A (ko) 2008-02-19
MX2007015779A (es) 2008-02-22
JP2008543912A (ja) 2008-12-04
EP1896445B1 (en) 2010-11-10
AU2006260997A1 (en) 2006-12-28
ES2353818T3 (es) 2011-03-07
IL188037A0 (en) 2008-03-20
US20100056513A1 (en) 2010-03-04
CN101203502A (zh) 2008-06-18
AU2006260997A8 (en) 2006-12-28
CA2612079A1 (en) 2006-12-28
US20060293318A1 (en) 2006-12-28
EP1896445A1 (en) 2008-03-12
ATE487707T1 (de) 2010-11-15
TW200740787A (en) 2007-11-01
WO2006136502A1 (en) 2006-12-28
KR100970055B1 (ko) 2010-07-16
BRPI0612125A2 (pt) 2010-10-19
DE602006018143D1 (de) 2010-12-23

Similar Documents

Publication Publication Date Title
AR054786A1 (es) (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1
DOP2009000133A (es) Derivados de indol como agonistas de los receptores s1p1
ECSP066856A (es) Compuestos novedosos como moduladores del receptor opioide
ECSP088511A (es) Agonistas del receptor del neuropeptido-2
CL2012003211A1 (es) Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso para preparar los compuestos; composicion farmaceutica que comprende a los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento o prevencion de diabetes tipo 2, obesidad y condiciones relacionadas
UY31063A1 (es) Derivados de n-[6-amino-5-aril-piridin -2-il]-carboxamida, composiciones conteniéndolos, procedimientos de preparación, itermedios utilizados en la preparación y aplicaciones.
ECSP034428A (es) Ciclopentanoindoles, composiciones conteniendo tales compuestos y su uso
CL2008002768A1 (es) Compuestos derivados de carboxiciclopropil-(bis-fenil-oxamidas); composicion farmaceutica que los contiene; procedimiento para la elaboracion de las composiciones y el uso de los compuestos en el tratamiento de diabetes y trastornos del sncentre otras enfermedades.
ECSP067021A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
ECSP088412A (es) Derivados de pirazina como moduladores de canal de sodio en el tratamiento del dolor
CL2011001263A1 (es) Compuestos derivados de pirimidinonas opcionalmente sustituidas; composicion farmaceutica que los comprende; y su uso como inhibidores de fosfodiesterasa 1 (pde1) para el tratamiento de enfermedades que involucran trastornos de la trayectoria intracelular del receptor de dopamina d1 como parkinson, alzheimer, depresion, enfermedad bipolar, hipertension, glaucoma.
ECSP088620A (es) 1h-indoles sustituidos por sulfonilo como ligandos para los receptores 5-hidroxitriptamina
CL2008002793A1 (es) Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
ECSP11011067A (es) Compuestos para el tratamiento de enfermedades y desórdenes oftalmológicos
CL2008002864A1 (es) Compuestos derivados de 2-amino-quinolina, antagonistas del receptor de serotonina 5-ht 5a; procedimiento de preparacion;composicion farmaceutica; y uso de los compuestos en la prevencion o el tratamiento de depresion,trastornos de ansiedad,esquizofrenia,trastornos de panico,trastornos de memoria,demencia,entre otros.
MX2022011354A (es) Compuestos de pirimidina fusionados como moduladores de kcc2.
SV2010003580A (es) Agonistas novedosos de los receptores de glucocorticoides
PA8493701A1 (es) Compuestos para tratar la obesidad
CL2011002206A1 (es) Compuestos derivados de benzofurano sustituidos, moduladores del señalador igf1 o activador de la proteina quinasa b; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades del snc, tales como alzheimer, entre otras.
CR10062A (es) Composiciones y metodos de tratamiento para trastornos del sistema nervioso central
ECSP045473A (es) Derivados de 1-(aminoalquil)-3-sulfonilindol y 1-aminoalquil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
UY29223A1 (es) Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación
CR10497A (es) Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38
UY29079A1 (es) Acidos fenoxiacéticos sustituidos, composiciones que los contienen, procedimientos de preparación y aplicaciones
CY1113759T1 (el) Ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2

Legal Events

Date Code Title Description
FA Abandonment or withdrawal